Core Viewpoint - McKesson Corporation (MCK) is perceived to receive insufficient attention from investors, particularly those focused on value investing, despite possessing characteristics of an ideal value investment [1] Company Characteristics - McKesson exhibits all the traits of a strong value investment opportunity, making it attractive for investors seeking undervalued stocks [1] Analyst Background - The analyst has over six years of experience in the investment sector, with a background in equity analysis across various industries, emphasizing the importance of understanding the narratives behind financial statements [1]

North America Equity Research December 2025 Healthcare Services 2026 Outlook: It's Different This Time: Potential for Margin Improvement and Policy Clarity Create a Positive Backdrop Conference Call Details Tuesday, December 17 @ 10:00am ET / 15:00 UK Dial-in Info: Please contact us or your JPM salesperson for details Replay Info: Available approximately 2-3 hours after the call ends Healthcare Services Lisa C. Gill AC (212) 622-6466 lisa.c.gill@jpmorgan.com Bloomberg JPMA GILL J.P. Morgan Securities LLC Ma ...

Cencora ( COR ) hasn’t received much coverage since early August, despite its growing relevance and strong fundamentals. The company remains largely overlooked by investors, yet I view it as one of the most attractive names in theHi there! I’m Narek, and I’ve been in the investment world for over six years. I started out as an equity analyst at European banks, digging into reports and learning how to spot value in the markets. I’ve worked across sectors — from telecom to industry — and found that behind eve ...

Core Viewpoint - McKesson (MCK) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for McKesson suggest an improvement in the company's underlying business, likely leading to an increase in stock price [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7][9]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions [9][10]. Recent Performance of McKesson - McKesson is expected to earn $38.05 per share for the fiscal year ending March 2026, with no year-over-year change, but the Zacks Consensus Estimate has increased by 2.3% over the past three months [8].

Core Viewpoint - Cardinal Health (CAH) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Cardinal suggest an improvement in the company's underlying business, likely leading to an increase in stock price [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7][9]. - Cardinal's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10]. Earnings Estimate Revisions for Cardinal - Cardinal is expected to earn $9.37 per share for the fiscal year ending June 2026, with no year-over-year change, but the Zacks Consensus Estimate has increased by 4.6% over the past three months [8].

Group 1 - Cencora, Inc. (NYSE: COR), previously known as AmerisourceBergen, is identified as a leading U.S. pharmaceutical distributor [1] - The company is favored for its stable business model and strategic investments in digital platforms and specialty medications [1] - A Buy rating is initiated for the company based on its current positioning and future potential [1]

Financial Performance - Revenues reached $97.8 billion, a 23% increase year-over-year[11] - Adjusted Earnings per Diluted Share increased by 5% to $8.26[11] - The company is raising its Fiscal 2026 Adjusted Earnings per Diluted Share outlook to a range of $37.10 to $37.90[11] Segment Results - U.S Pharmaceutical revenues increased by 25% to $89.954 billion, with adjusted segment operating profit up by 17% to $950 million[15] - Prescription Technology Solutions revenues grew by 16% to $1.434 billion, and adjusted segment operating profit increased by 21% to $269 million[16] - Medical-Surgical Solutions revenues increased by 2% to $2.701 billion, with adjusted segment operating profit up by 22% to $244 million[17] Capital Allocation - The Board of Directors approved a 15% increase in the quarterly dividend[11] - Approximately $2.5 billion is anticipated for share repurchases in Fiscal Year 2026[27]

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying the right ones can be challenging due to associated risks and volatility [1] Group 1: Company Overview - McKesson (MCK) is highlighted as a recommended growth stock with a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 16%, with projected EPS growth of 12.7% this year, significantly higher than the industry average of 6.9% [5] Group 2: Financial Metrics - McKesson's asset utilization ratio (sales-to-total-assets ratio) is 4.95, indicating that the company generates $4.95 in sales for every dollar in assets, compared to the industry average of 0.72 [6] - The company's sales are expected to grow by 13.1% this year, outpacing the industry average growth of 4.5% [7] Group 3: Earnings Estimates - There has been a positive trend in earnings estimate revisions for McKesson, with the current-year earnings estimates increasing by 0.1% over the past month [8] - McKesson has achieved a Zacks Rank of 2 (Buy) and a Growth Score of A, indicating strong potential for growth investors [10]

Core Viewpoint - Growth investors are increasingly focused on identifying stocks with above-average financial growth, which can lead to solid returns, but finding such stocks is challenging due to their inherent risks and volatility [1] Group 1: Company Overview - McKesson is identified as a promising growth stock, supported by a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 16%, with projected EPS growth of 12.6% this year, significantly outperforming the industry average of 1.3% [5] - McKesson's sales are expected to grow by 13% this year, compared to the industry average of 1.1% [7] Group 2: Key Metrics - The asset utilization ratio for McKesson is 4.95, indicating that the company generates $4.95 in sales for every dollar in assets, which is substantially higher than the industry average of 0.72 [6] - The current-year earnings estimates for McKesson have been revised upward, with the Zacks Consensus Estimate increasing by 0.1% over the past month [9] Group 3: Investment Potential - McKesson has achieved a Zacks Rank of 2 (Buy) and a Growth Score of A, indicating its potential as an outperformer and a solid choice for growth investors [11]

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying strong candidates can be challenging due to associated risks and volatility [1] Group 1: Company Overview - McKesson (MCK) is highlighted as a recommended growth stock, possessing a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 16%, with projected EPS growth of 12.5% this year, surpassing the industry average of 8.2% [4] Group 2: Key Growth Metrics - The asset utilization ratio for McKesson is 4.95, indicating that the company generates $4.95 in sales for every dollar in assets, significantly higher than the industry average of 0.77 [5] - McKesson's sales are expected to grow by 13% this year, compared to the industry average of 3.2% [6] Group 3: Earnings Estimate Revisions - There is a positive trend in earnings estimate revisions for McKesson, with the current-year earnings estimates increasing by 1.7% over the past month [7] Group 4: Investment Positioning - McKesson has achieved a Growth Score of A and a Zacks Rank of 2, positioning it well for potential outperformance in the growth stock category [9]